Literature DB >> 23586898

Aberrant microRNA expression in multiple myeloma.

Konstantinos Dimopoulos1, Peter Gimsing, Kirsten Grønbæk.   

Abstract

Multiple myeloma (MM) is a devastating disease with a complex biology, and in spite of improved survivability by novel treatment strategies over the last decade, MM is still incurable by current therapy. MicroRNAs (miRNAs) are small, non-coding RNA molecules that regulate gene expression at a post-transcriptional level. More than half of all protein coding genes are estimated to be controlled by miRNAs, and their expression is frequently deregulated in many diseases, including cancer. Recent studies have reported aberrant miRNA expression patterns in MM, and the function of individual miRNAs in MM has been investigated in detail in cell culture and animal models. Here, we review the current knowledge on the role of miRNAs in MM pathogenesis and discuss their potential as prognostic biomarkers and targets for treatment.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  epigenetics; expression; miRNA; multiple myeloma

Mesh:

Substances:

Year:  2013        PMID: 23586898     DOI: 10.1111/ejh.12124

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  25 in total

1.  Identification of key genes and construction of microRNA-mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis.

Authors:  Hongyu Gao; Huihan Wang; Wei Yang
Journal:  Int J Hematol       Date:  2017-03-18       Impact factor: 2.490

2.  Expressions of miR-181a and miR-20a in RPMI8226 cell line and their potential as biomarkers for multiple myeloma.

Authors:  Jing Peng; Asmitananda Thakur; Shuo Zhang; Yuanfeng Dong; Xiaoqin Wang; Ruili Yuan; Kaige Zhang; Xuan Guo
Journal:  Tumour Biol       Date:  2015-06-02

Review 3.  Novel therapeutic strategies for multiple myeloma.

Authors:  Naoya Mimura; Teru Hideshima; Kenneth C Anderson
Journal:  Exp Hematol       Date:  2015-06-26       Impact factor: 3.084

Review 4.  MicroRNA Transfer Between Bone Marrow Adipose and Multiple Myeloma Cells.

Authors:  Luna Soley; Carolyne Falank; Michaela R Reagan
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

5.  Downregulation of MicroRNA-152 contributes to high expression of DKK1 in multiple myeloma.

Authors:  Yinyin Xu; Bingda Chen; Suraj K George; Beizhong Liu
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

Review 6.  Crosstalk between microRNA30a/b/c/d/e-5p and the canonical Wnt pathway: implications for multiple myeloma therapy.

Authors:  Jian-Jun Zhao; Ruben D Carrasco
Journal:  Cancer Res       Date:  2014-09-16       Impact factor: 12.701

7.  Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma.

Authors:  Mu Hao; Meirong Zang; Erik Wendlandt; Yan Xu; Gang An; Dasen Gong; Fei Li; Fang Qi; Yanru Zhang; Ye Yang; Fenghuang Zhan; Lugui Qiu
Journal:  Int J Cancer       Date:  2014-09-19       Impact factor: 7.396

Review 8.  MicroRNAs in B-cells: from normal differentiation to treatment of malignancies.

Authors:  Sara Correia Marques; Maria Bach Laursen; Julie Støve Bødker; Malene Krag Kjeldsen; Steffen Falgreen; Alexander Schmitz; Martin Bøgsted; Hans Erik Johnsen; Karen Dybkaer
Journal:  Oncotarget       Date:  2015-01-01

9.  Validating reference microRNAs for normalizing qRT-PCR data in bovine oocytes and preimplantation embryos.

Authors:  Mahdi Mahdipour; Helena T A van Tol; Tom A E Stout; Bernard A J Roelen
Journal:  BMC Dev Biol       Date:  2015-06-12       Impact factor: 1.978

Review 10.  Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.

Authors:  Jahangir Abdi; Guoan Chen; Hong Chang
Journal:  Oncotarget       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.